GENFIT: ordinary and extraordinary SHAREHOLDERS’ meeting of june 16, 2017 – AVAILABILITY OF PREPARATORY DOCUMENTS Lille (France), Cambridge (Massachusetts, United States), May 19, 2017 – GENFIT (Euronext: GNFT – ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the […]
GENFIT: ordinary and extraordinary SHAREHOLDERS’ meeting of june 16, 2017 – AVAILABILITY OF PREPARATORY DOCUMENTS
Lille (France), Cambridge (Massachusetts, United States), May 19, 2017 – GENFIT (Euronext: GNFT – ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announced the availability of preparatory documents for the Ordinary and Extraordinary Shareholders’ Meeting (the “Shareholders’ Meeting”) to be held on June 16th, 2017, at 10:30am, at the Faculty of Pharmaceutical & Biological Sciences of Lille, located Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France.
The Notice of Meeting comprising the agenda and resolutions drafts was published in the French official legal bulletin (“BALO”) of May 12, 2017 and has been available on the Company’s website since that date, in the documentation center (http://www.genfit.com/investors/documentation-center/).
All documentation regarding this Shareholders’ Meeting is available to shareholders in accordance with existing regulations, and is available on the Company’s website, in the documentation center (http://www.genfit.com/investors/documentation-center/).
Documents listed in Article R.225-83 of the French commercial code are available to shareholders in accordance with existing regulations.
Shareholders are invited to contact the toll-free (France only) number starting Monday, May 22, 2017, with any questions regarding how to participate in the Meeting: 0800 940 651
GENFIT is a biopharmaceutical company focused on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT’s R&D efforts are focused on bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH – Nonalcoholic steatohepatitis) and more generally the gastro-intestinal arena. GENFIT’s approach combines novel treatments and biomarkers. Its lead proprietary compound, elafibranor, is currently in a Phase 3 study. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 130 employees. GENFIT is a public company listed in compartment B of Euronext’s regulated market in Paris (Euronext: GNFT – ISIN: FR0004163111). www.genfit.com
Forward Looking Statement / Disclaimer
This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, including related to biomarkers, progression of, and results of clinical data from, the RESOLVE-IT trial, review and approvals by regulatory authorities, such as the FDA or the EMA, regarding in particular, elafibranor in NASH and PBC, as well as other indications, and biomarkers, the success of any inlicensing strategies, the Company’s continued ability to raise capital to fund its development, as well as those discussed or identified in the Company’s public filings with the AMF, including those listed under Section 4 “Main Risks and Uncertainties” of the Company’s 2016 Registration Document registered with the French Autorité des marchés financiers on April 28, 2017 under n° R.17-034, which is available on GENFIT’s website (www.genfit.com) and on the website of the AMF (www.amf-france.org). Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.
GENFIT | Jean-François Mouney – Chairman & CEO | +333 2016 4000
MILESTONES – Press Relations | Bruno Arabian | +331 8362 3484 / +336 8788 4726 – email@example.com
Source: Health Care